Overexpression of MiR-210 is Associated with Poor Prognosis of Acute Myeloid Leukemia

Overview

Journal Med Sci Monit

Specialties General Medicine
Pathology

Date 2015 Nov 10

PMID 26549593

Citations 23

Authors

Xiaoqiong Tang

Liping Chen

Xinyu Yan

Yuanjie Li

Yuanlin Xiong

Xiaohui Zhou

Affiliations

Soon will be listed here.

Abstract

Background: MicroRNAs play important roles in regulation of the initiation and progression of AML. MiR-210 is closely related with cancer development; however, whether miR-210 expression level correlates with clinical correlation in AML is unknown. Thus, the aim of this study was to investigate the potential relationship between miR-210 expression and AML prognosis.

Material And Methods: Real-time quantitative PCR was carried out to examine the expression level of miR-210 in bone marrow and serum obtained from AML patients and healthy controls. Then the correlation between miR-210 expression and a variety of important clinical parameters (such as overall survival, relapse-free survival, and prognostic value) were further studied.

Results: The expression level of miR-210 was significantly higher in the bone marrow and serum of AML patients than that of healthy controls (p<0.001). Moreover, miR-210 expression was associated with various AML clinicopathological parameters, including FAB classification and cytogenetics. The serum miR-210 expression level was reduced significantly when the patients achieved complete remission (p=0.02). The high miR-210 expression group had both poorer relapse-free survival (p=0.015) and worse overall survival (p=0.008). In the multivariate analysis model, miR-210 was identified as an independent prognostic marker.

Conclusions: MiR-210 up-regulation was associated with poor prognosis in AML and it might be useful as a marker for predicting the clinical outcome of AML patients.

Citing Articles

MircoRNAs predict and modulate responses to chemotherapy in leukemic patients.

Ellakwa D, Abdelmalek M, Mostafa M, Ellakwa T, Wadan A Naunyn Schmiedebergs Arch Pharmacol. 2025; .

PMID: 39808312 DOI: 10.1007/s00210-024-03675-7.

Bone marrow microRNA-34a is a good indicator for response to treatment in acute myeloid leukemia.

Abdellateif M, Hassan N, Kamel M, El-Meligui Y Oncol Res. 2024; 32(3):577-584.

PMID: 38361758 PMC: 10865737. DOI: 10.32604/or.2023.043026.

MicroRNAs Associated with a Bad Prognosis in Acute Myeloid Leukemia and Their Impact on Macrophage Polarization.

Jimbu L, Mesaros O, Joldes C, Neaga A, Zaharie L, Zdrenghea M Biomedicines. 2024; 12(1).

PMID: 38255226 PMC: 10813737. DOI: 10.3390/biomedicines12010121.

The Mechanism of Anti-Tumor Activity of 6-Morpholino- and 6-Amino-9-Sulfonylpurine Derivatives on Human Leukemia Cells.

Leventic M, Opacak-Bernardi T, Rastija V, Matic J, Saftic D, Ban Z Molecules. 2023; 28(16).

PMID: 37630388 PMC: 10458232. DOI: 10.3390/molecules28166136.

Liquid biopsies and minimal residual disease in myeloid malignancies.

Allam S, Nasr K, Khalid F, Shah Z, Khan Suheb M, Mulla S Front Oncol. 2023; 13:1164017.

PMID: 37213280 PMC: 10196237. DOI: 10.3389/fonc.2023.1164017.

References

Qian J, Lin J, Qian W, Ma J, Qian S, Li Y . Overexpression of miR-378 is frequent and may affect treatment outcomes in patients with acute myeloid leukemia. Leuk Res. 2013; 37(7):765-8. DOI: 10.1016/j.leukres.2013.03.014. View

Tsuchiya S, Fujiwara T, Sato F, Shimada Y, Tanaka E, Sakai Y . MicroRNA-210 regulates cancer cell proliferation through targeting fibroblast growth factor receptor-like 1 (FGFRL1). J Biol Chem. 2010; 286(1):420-8. PMC: 3013001. DOI: 10.1074/jbc.M110.170852. View

Zhan M, Li Y, Hu B, He X, Huang J, Zhao Y . Serum microRNA-210 as a predictive biomarker for treatment response and prognosis in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. J Vasc Interv Radiol. 2014; 25(8):1279-1287.e1. DOI: 10.1016/j.jvir.2014.04.013. View

Qin Q, Furong W, Baosheng L . Multiple functions of hypoxia-regulated miR-210 in cancer. J Exp Clin Cancer Res. 2014; 33:50. PMC: 4060094. DOI: 10.1186/1756-9966-33-50. View

Qu A, Du L, Yang Y, Liu H, Li J, Wang L . Hypoxia-inducible MiR-210 is an independent prognostic factor and contributes to metastasis in colorectal cancer. PLoS One. 2014; 9(3):e90952. PMC: 3954583. DOI: 10.1371/journal.pone.0090952. View

Min W, Wang B, Li J, Han J, Zhao Y, Su W . The expression and significance of five types of miRNAs in breast cancer. Med Sci Monit Basic Res. 2014; 20:97-104. PMC: 4117676. DOI: 10.12659/MSMBR.891246. View

Samaan S, Khella H, Girgis A, Scorilas A, Lianidou E, Gabril M . miR-210 is a prognostic marker in clear cell renal cell carcinoma. J Mol Diagn. 2015; 17(2):136-44. DOI: 10.1016/j.jmoldx.2014.10.005. View

Zhu C, Wang Y, Kuai W, Sun X, Chen H, Hong Z . Prognostic value of miR-29a expression in pediatric acute myeloid leukemia. Clin Biochem. 2012; 46(1-2):49-53. DOI: 10.1016/j.clinbiochem.2012.09.002. View

Camps C, Buffa F, Colella S, Moore J, Sotiriou C, Sheldon H . hsa-miR-210 Is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin Cancer Res. 2008; 14(5):1340-8. DOI: 10.1158/1078-0432.CCR-07-1755. View

10.

Macfarlane L, Murphy P . MicroRNA: Biogenesis, Function and Role in Cancer. Curr Genomics. 2011; 11(7):537-61. PMC: 3048316. DOI: 10.2174/138920210793175895. View

11.

Dang K, Myers K . The role of hypoxia-induced miR-210 in cancer progression. Int J Mol Sci. 2015; 16(3):6353-72. PMC: 4394536. DOI: 10.3390/ijms16036353. View

12.

Mei Y, Gao C, Wang K, Cui L, Li W, Zhao X . Effect of microRNA-210 on prognosis and response to chemotherapeutic drugs in pediatric acute lymphoblastic leukemia. Cancer Sci. 2014; 105(4):463-72. PMC: 4317805. DOI: 10.1111/cas.12370. View

13.

Lai N, Wu D, Fang X, Lin Y, Chen S, Li Z . Serum microRNA-210 as a potential noninvasive biomarker for the diagnosis and prognosis of glioma. Br J Cancer. 2015; 112(7):1241-6. PMC: 4385967. DOI: 10.1038/bjc.2015.91. View

14.

Zhang Z, Sun H, Dai H, Walsh R, Imakura M, Schelter J . MicroRNA miR-210 modulates cellular response to hypoxia through the MYC antagonist MNT. Cell Cycle. 2009; 8(17):2756-68. DOI: 10.4161/cc.8.17.9387. View

15.

Gee H, Camps C, Buffa F, Patiar S, Winter S, Betts G . hsa-mir-210 is a marker of tumor hypoxia and a prognostic factor in head and neck cancer. Cancer. 2010; 116(9):2148-58. DOI: 10.1002/cncr.25009. View

16.

Devlin C, Greco S, Martelli F, Ivan M . miR-210: More than a silent player in hypoxia. IUBMB Life. 2011; 63(2):94-100. PMC: 4497508. DOI: 10.1002/iub.427. View

17.

Chen J, Odenike O, Rowley J . Leukaemogenesis: more than mutant genes. Nat Rev Cancer. 2009; 10(1):23-36. PMC: 2972637. DOI: 10.1038/nrc2765. View

18.

Eilertsen M, Andersen S, Al-Saad S, Richardsen E, Stenvold H, Hald S . Positive prognostic impact of miR-210 in non-small cell lung cancer. Lung Cancer. 2013; 83(2):272-8. DOI: 10.1016/j.lungcan.2013.11.005. View

19.

Verhaak R, Valk P . Genes predictive of outcome and novel molecular classification schemes in adult acute myeloid leukemia. Cancer Treat Res. 2010; 145:67-83. DOI: 10.1007/978-0-387-69259-3_5. View

20.

Papaconstantinou I, Manta A, Gazouli M, Lyberopoulou A, Lykoudis P, Polymeneas G . Expression of microRNAs in patients with pancreatic cancer and its prognostic significance. Pancreas. 2012; 42(1):67-71. DOI: 10.1097/MPA.0b013e3182592ba7. View